<DOC>
	<DOCNO>NCT02554851</DOCNO>
	<brief_summary>Phase III clinical trial , multicenter , control , randomize , double-blind , two parallel group ( experimental control ) . Both study group receive standard therapy currently available treatment center diabetic foot ulcer ( DFU ) . Associate standard therapy , give recombinant human Epidermal Growth Factor ( rhEGF ) experimental group control group , give formulation without pharmacological effect ( placebo ) order mask control intralesional application . Participants type 1 type 2 diabetes mellitus ( DM ) diagnose DFU least 4 week , treat referral center participate study , agree participate reading , understand signing Informed Consent ( IC ) ; meet inclusion criterion ; present exclusion criterion . The Informed Consent ( IC ) apply potential participant , recommend regulation ethical consensus begin procedure related clinical trial . In early week , participant evaluate research center study team ( doctor / staff ) . The number visit determine investigator , thus ensure appropriate assistance participant , avoid complication DFU . By meet eligibility requirement ( inclusion exclusion criterion ) , participant undergo thorough evaluation DFU start treatment . This assessment precisely classify condition ulcer treatment provide relevant information statistical analysis protocol . If eligible , participant randomly set treatment arm ( placebo rhEGF ) administration investigational product associate predefined standardized outpatient therapy initiate . This administration occur three time per week DFU scar , exceed 8 week treatment ( T.01 T.08 ) .The study randomize balance accord type size DFU . This balance necessary ensure treatment group homogeneous participant different condition . All participant apply establish standard therapy treatment DFU . The objective provide regular care heal reduce possible bias efficacy analysis product safety . After treatment period ( last dose experimental drug ) participant start follow-up period , 16 week duration . The participant shall subject weekly visit ongoing assessment DFU , however , accord investigator , may result unscheduled visit assess local general clinical event . After monitor period , participant observe 24 additional week , visit every 4 week ( E.01 E.24 ) begin one week last visit follow-up . This period intend assess possible event related efficacy safety happen period , mainly analysis secondary endpoint .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Intralesional Recombinant Human Epidermal Growth Factor ( rhEGF ) Subjects With Diabetic Foot Ulcer .</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . DM type 1 2 diagnosis 2 . DFU persist minimum 4 week If participant one DFU , treat one large extension follow inclusion exclusion criterion . 3 . DFU 's rating accord PEDIS system : Perfusion : grade 1 2 ; Extension : Area â‰¥ 2 cm2 ; Depth : grade 2 3 ; Infection : grade 1 2 ; Sensitivity : grade 2 If consent participant classify infection grade 3 without presence osteomyelitis , possible treat antibiotic empirically . However , randomization make treatment infection regress grade 1 2 ; 1 . Age le 18 year ; 2 . Pregnancy breastfeeding ( woman childbearing age need use contraception method ) ; 3 . Evidence bone involvement : direct visualization bone structure ; positive survey ( probe bone ) ; image investigation ( simple xray MRI ) ; 4 . Urgent imminent need amputation ; 5 . Eminent indication revascularization ; 6 . Glycated hemoglobin ( HbA1c ) count great 11 % 7 . Use drug affect contribute heal ulcer corticosteroid ; immunosuppressive ; chemotherapy ; growth factor ; 8 . Clinical sign malnutrition serum albumin &lt; 30 g / L ; 9 . Angina pectoris classify 3 4 ( accord Canadian Cardiovascular Society Angina Classification ) ; 10 . Congestive heart failure class IV ( accord New York Heart Association ) ; 11 . Severe hepatic impairment , define ALT / AST great 5 ( five ) time normal maximum reference value ; 12 . Acute renal failure , define serum creatinine level equal high 1.5 time baseline value last 7 day ( accord KDIGO RIFLE classification ) ; 13 . Endstage renal disease ( creatinine clearance equal low 30 ml / min dialysis ) ; 14 . History suspect neoplasia ( accord previous laboratory test , image biopsy ) ; 15 . Psychiatric disorder may alter participant evaluation , prevent proper consent / cognitive aspect demonstrate possibility noncompliance treatment adoption aseptic criterion ; 16 . Occurrence follow event 30 day prior inclusion protocol : participation clinical study ; hypoglycemic coma ( blood glucose less equal 30 mg / dL loss consciousness need help ) ; diabetic ketoacidosis hyperosmolar state within 30 day prior inclusion ; 17 . Occurrence follow event 60 day prior inclusion protocol : hospitalization acute coronary syndrome , percutaneous intervention ( eg cardiac , cerebrovascular , aortic ) great cardiac surgery ; myocardial infarction ; cerebrovascular accident ; cardiac arrest ; sustain ventricular tachycardia ; acute coronary syndrome , investigator opinion ; uncontrolled severe hypertension , define systolic blood pressure equal high 180 mmHg / diastolic blood pressure equal high 110 mmHg ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>